detail look organ pbm growth
pbm oper follow thursday morn solid beat rais ci stock
finish day vs possibl caus manag
commentari around y/i organ growth profil mainli pbm
busi specif cfo eric palmer remark like-for-lik health servic
comparison singl digit percentag quarter pattern
expect flip singl digit back half year best-effort y/i
comparison think declin first half
believ midpoint guidanc impli y/i growth
trajectori back half year figur detail bridg
reconcil esrx adjust ebitda earn show
underli core growth pbm
what drive pbm management expect earn season
driven suppli chain initi take full effect strong specialti
pharmaci perform includ full run-rat benefit specialti gener introduc
earlier year sg synergi earn driver off-set
mn strand overhead cost associ expir contract
also back-end weight follow-up call ci management sens
suppli chain initi part relat lower cost drug procur
exampl combin mail order busi could abl achiev better drug price
esrx particip wbad discuss execut drug
distributor week receiv strong sens buy group gain
traction also ci/esrx abl capit consolid legaci cigna
mail order drug inventori procur esrx mail rx procur ci volum
distributor esrx volum
reiter ow follow today result increas ep
maintain ep estim respect
maintain ow rate pt price-to-earnings ep
ci quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight price target base
price-to-earnings ep compani
continu leverag strength control
medic cost continu gain market share
commerci busi return industri growth
medicar
upsid case reflect favor medic
cost trend outlook higher expect share
gain commerci segment
downsid case reflect risk associ
increas cost trend agress commerci price
lower expect commerci growth
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
ci investor day bridg esrx ebitda guidanc project health servic earn growth
ci investor day present note includ resegment cigna deliveri express script part adjust
pbm commentari earn call
year-on-year character result second quarter versu second quarter singl digit
percentag quarter note look ahead might expect third quarter expect
pattern flip expect mid-singl digit singl digit term perform health servic
busi rel express script piec last year third quarter bring capabl on-line effect
suppli chain initi drive us growth back half year cfo eric palmer
earn consolid oper metricsadjust incom oper revenu expens tax oper metricsadjust incom oper pre-taxintegr medic pre-tax incom servic pre-tax incom custom pharmaci bnmedic barclay
 financi pharmaci invest adjust changetot expensesmed benefit medic servic excl intang oper incom loss attribut includ margin expens adjust margin tax net incom margin share fulli barclay
 pharmaci invest adjust changetot expensesmed benefit medic servic excl intang oper incom loss attribut includ margin expens adjust margin tax net incom margin share fulli barclay
integr medic medic invest oper loss attribut adjust margin assumptionsfe revenenu loss subject py sg servic servic lactualactualprojectedprojectedprojectedadjust pharmaci invest servic oper loss attribut expens adjust margin profit excl transit assumptionspharmaci servic cost barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
